Catalyst Biosciences Inc (NASDAQ:CBIO) saw some unusual options trading activity on Wednesday. Stock traders purchased 1,175 call options on the stock. This is an increase of 1,235% compared to the typical volume of 88 call options.

NASDAQ:CBIO opened at $10.62 on Thursday. Catalyst Biosciences has a one year low of $4.15 and a one year high of $37.00. The stock has a market capitalization of $122.06 million, a PE ratio of -1.43 and a beta of 2.32.

Catalyst Biosciences (NASDAQ:CBIO) last posted its quarterly earnings results on Thursday, August 2nd. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating the consensus estimate of ($0.62) by $0.08. Catalyst Biosciences had a negative net margin of 2,983.40% and a negative return on equity of 27.51%. sell-side analysts expect that Catalyst Biosciences will post -2.47 earnings per share for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of CBIO. Quantitative Systematic Strategies LLC bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth approximately $120,000. Rhumbline Advisers bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth approximately $136,000. DRW Securities LLC bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth approximately $152,000. Alps Advisors Inc. bought a new position in shares of Catalyst Biosciences during the 2nd quarter worth approximately $201,000. Finally, Wells Fargo & Company MN raised its stake in shares of Catalyst Biosciences by 148.3% during the 1st quarter. Wells Fargo & Company MN now owns 8,940 shares of the biopharmaceutical company’s stock worth $231,000 after acquiring an additional 5,340 shares in the last quarter. Hedge funds and other institutional investors own 67.98% of the company’s stock.

Several equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a report on Wednesday, July 25th. Chardan Capital restated a “buy” rating and issued a $35.00 price target on shares of Catalyst Biosciences in a report on Tuesday, June 19th. ValuEngine upgraded shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a report on Friday, June 1st. BidaskClub upgraded shares of Catalyst Biosciences from a “sell” rating to a “hold” rating in a report on Tuesday, June 19th. Finally, B. Riley lowered shares of Catalyst Biosciences from a “buy” rating to a “neutral” rating and reduced their price target for the company from $44.00 to $12.50 in a report on Thursday, June 21st. Three investment analysts have rated the stock with a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average target price of $19.50.

About Catalyst Biosciences

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

Featured Article: Tariff

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.